Exchange: NASDAQ Global Market Sector: Healthcare Industry: Drug Manufacturers - General
-31.16% $0.0475
/ 6 sep 2022 @ 15:59
RATING 2022-11-08 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Sell | |
DE: | Strong Sell | |
P/E: | Neutral | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
Revenue | n/a | n/a | ||||
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.0170 | sector: PE 0 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -0.0170 | industry: PE 0 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.0165 - 0.0785 ( +/- 65.26%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-06-07 | Prygocki Mark A Sr | Buy | 1 922 | Common Stock |
2022-06-07 | Prygocki Mark A Sr | Buy | 4 805 | Stock Option (Right to Buy) |
2022-06-07 | Prygocki Mark A Sr | Buy | 4 805 | Stock Option (Right to Buy) |
2022-06-07 | Murphy Kimberly M | Buy | 4 805 | Stock Option (Right to Buy) |
2022-06-07 | Amory John Kenneth | Buy | 1 922 | Common Stock |
INSIDER POWER |
---|
49.59 |
Last 40 transactions |
Buy: 18 969 756 | Sell: 5 390 412 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.0475 (-31.16% ) |
Volume | 2.74 mill |
Avg. Vol. | 0 mill |
% of Avg. Vol | 0 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.